Baxter International (NYSE:BAX) Issues Quarterly Earnings Results, Beats Estimates By $0.06 EPS

Baxter International (NYSE:BAX - Get Free Report) issued its quarterly earnings data on Thursday. The medical instruments supplier reported $0.58 earnings per share for the quarter, topping the consensus estimate of $0.52 by $0.06, Zacks reports. Baxter International had a net margin of 0.77% and a return on equity of 18.30%. The company had revenue of $2.75 billion for the quarter, compared to analysts' expectations of $2.67 billion. Baxter International updated its FY 2025 guidance to 2.450-2.550 EPS and its Q1 2025 guidance to 0.470-0.500 EPS.

Baxter International Stock Up 1.3 %

Shares of BAX stock traded up $0.43 on Friday, reaching $33.87. 7,264,381 shares of the company were exchanged, compared to its average volume of 4,927,193. The company has a market cap of $17.29 billion, a price-to-earnings ratio of 169.33, a PEG ratio of 9.83 and a beta of 0.61. The company has a 50-day moving average of $30.65 and a 200-day moving average of $34.14. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.43 and a quick ratio of 1.09. Baxter International has a one year low of $28.33 and a one year high of $44.01.

Baxter International Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 1st. Stockholders of record on Friday, February 28th will be given a dividend of $0.17 per share. The ex-dividend date is Friday, February 28th. This represents a $0.68 dividend on an annualized basis and a dividend yield of 2.01%. Baxter International's dividend payout ratio (DPR) is presently 340.02%.

Wall Street Analyst Weigh In

BAX has been the topic of several analyst reports. Citigroup reduced their price objective on shares of Baxter International from $37.00 to $35.00 and set a "neutral" rating on the stock in a research note on Wednesday, December 11th. JPMorgan Chase & Co. reduced their price objective on shares of Baxter International from $38.00 to $36.00 and set a "neutral" rating on the stock in a research note on Friday. StockNews.com cut shares of Baxter International from a "buy" rating to a "hold" rating in a research note on Monday, November 11th. Stifel Nicolaus cut their price target on shares of Baxter International from $46.00 to $38.00 and set a "buy" rating on the stock in a research report on Monday, November 11th. Finally, Barclays started coverage on shares of Baxter International in a research report on Thursday. They set an "overweight" rating and a $39.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $38.80.

About Baxter International

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.